Loading…
Association of endostatin with mortality in patients with chronic heart failure
Background Experimental data imply that in decompensated heart failure (HF), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF pat...
Saved in:
| Published in: | European journal of clinical investigation 2014-02, Vol.44 (2), p.125-135 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3 |
| container_end_page | 135 |
| container_issue | 2 |
| container_start_page | 125 |
| container_title | European journal of clinical investigation |
| container_volume | 44 |
| creator | Gouya, Ghazaleh Siller-Matula, Jolanta M. Fritzer-Szekeres, Monika Neuhold, Stephanie Storka, Angela Neuhofer, Lisa M. Clodi, Martin Hülsmann, Martin Pacher, Richard Wolzt, Michael |
| description | Background
Experimental data imply that in decompensated heart failure (HF), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF patients.
Methods
In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow‐up of 31 months.
Results
One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all‐cause mortality [HR 8·7 (95% CI 2·5–30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT‐proBNP were above the calculated cut‐off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [HR 40·8 (95% CI 4·7–354·6); P = 0·001] compared with values lower than the cut‐offs.
Conclusions
Serum endostatin concentrations are independently associated with all‐cause mortality. Furthermore, combination of endostatin and NT‐proBNP discriminates patients at high risk. |
| doi_str_mv | 10.1111/eci.12197 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629952635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1629952635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3</originalsourceid><addsrcrecordid>eNp1kEFP3DAQhS3UCrbAgT9Q5VgOgbEd28kRrWChWpUeChwtx5loXbLxYnsF--8xDXDrXEbz5pun0SPkhMIZzXWO1p1RRhu1R2aUS1EyLtkXMgOgVckaxQ7Itxj_AkBNOdsnB6yidc1ZMyO3FzF660xyfix8X-DY-ZjyOBbPLq2KtQ_JDC7tiqxsso5jitPKroIfnS1WaEIqeuOGbcAj8rU3Q8Tj935I7q4u_8yvy-Xt4mZ-sSwtl1yVLVheATQUlVBg66ruraGdQrBV_legBYMgRVXXFqWsQIlKoOlbaKHrZMsPyY_JdxP80xZj0msXLQ6DGdFvo6aSNY1gkouMnk6oDT7GgL3eBLc2Yacp6Lf8dM5P_8svs9_fbbftGrtP8iOwDJxPwLMbcPd_J305v_mwLKcLFxO-fF6Y8Kil4kroh18Lff97Ds3Dz6Ve8Fe0RYkU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629952635</pqid></control><display><type>article</type><title>Association of endostatin with mortality in patients with chronic heart failure</title><source>Wiley</source><creator>Gouya, Ghazaleh ; Siller-Matula, Jolanta M. ; Fritzer-Szekeres, Monika ; Neuhold, Stephanie ; Storka, Angela ; Neuhofer, Lisa M. ; Clodi, Martin ; Hülsmann, Martin ; Pacher, Richard ; Wolzt, Michael</creator><creatorcontrib>Gouya, Ghazaleh ; Siller-Matula, Jolanta M. ; Fritzer-Szekeres, Monika ; Neuhold, Stephanie ; Storka, Angela ; Neuhofer, Lisa M. ; Clodi, Martin ; Hülsmann, Martin ; Pacher, Richard ; Wolzt, Michael</creatorcontrib><description>Background
Experimental data imply that in decompensated heart failure (HF), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF patients.
Methods
In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow‐up of 31 months.
Results
One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all‐cause mortality [HR 8·7 (95% CI 2·5–30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT‐proBNP were above the calculated cut‐off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [HR 40·8 (95% CI 4·7–354·6); P = 0·001] compared with values lower than the cut‐offs.
Conclusions
Serum endostatin concentrations are independently associated with all‐cause mortality. Furthermore, combination of endostatin and NT‐proBNP discriminates patients at high risk.</description><identifier>ISSN: 0014-2972</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1111/eci.12197</identifier><identifier>PMID: 24188329</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; All-cause mortality ; Biomarkers - metabolism ; Chronic Disease ; endostatin ; Endostatins - metabolism ; Epidemiologic Methods ; Female ; heart failure ; Heart Failure - mortality ; Hospitalization - statistics & numerical data ; Humans ; Male ; Middle Aged ; Natriuretic Agents - pharmacology ; Natriuretic Peptide, Brain - metabolism ; Natriuretic Peptide, Brain - pharmacology ; Peptide Fragments - metabolism ; Prognosis ; Young Adult</subject><ispartof>European journal of clinical investigation, 2014-02, Vol.44 (2), p.125-135</ispartof><rights>2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd</rights><rights>2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3</citedby><cites>FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24188329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gouya, Ghazaleh</creatorcontrib><creatorcontrib>Siller-Matula, Jolanta M.</creatorcontrib><creatorcontrib>Fritzer-Szekeres, Monika</creatorcontrib><creatorcontrib>Neuhold, Stephanie</creatorcontrib><creatorcontrib>Storka, Angela</creatorcontrib><creatorcontrib>Neuhofer, Lisa M.</creatorcontrib><creatorcontrib>Clodi, Martin</creatorcontrib><creatorcontrib>Hülsmann, Martin</creatorcontrib><creatorcontrib>Pacher, Richard</creatorcontrib><creatorcontrib>Wolzt, Michael</creatorcontrib><title>Association of endostatin with mortality in patients with chronic heart failure</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description>Background
Experimental data imply that in decompensated heart failure (HF), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF patients.
Methods
In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow‐up of 31 months.
Results
One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all‐cause mortality [HR 8·7 (95% CI 2·5–30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT‐proBNP were above the calculated cut‐off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [HR 40·8 (95% CI 4·7–354·6); P = 0·001] compared with values lower than the cut‐offs.
Conclusions
Serum endostatin concentrations are independently associated with all‐cause mortality. Furthermore, combination of endostatin and NT‐proBNP discriminates patients at high risk.</description><subject>Adult</subject><subject>All-cause mortality</subject><subject>Biomarkers - metabolism</subject><subject>Chronic Disease</subject><subject>endostatin</subject><subject>Endostatins - metabolism</subject><subject>Epidemiologic Methods</subject><subject>Female</subject><subject>heart failure</subject><subject>Heart Failure - mortality</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Natriuretic Agents - pharmacology</subject><subject>Natriuretic Peptide, Brain - metabolism</subject><subject>Natriuretic Peptide, Brain - pharmacology</subject><subject>Peptide Fragments - metabolism</subject><subject>Prognosis</subject><subject>Young Adult</subject><issn>0014-2972</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kEFP3DAQhS3UCrbAgT9Q5VgOgbEd28kRrWChWpUeChwtx5loXbLxYnsF--8xDXDrXEbz5pun0SPkhMIZzXWO1p1RRhu1R2aUS1EyLtkXMgOgVckaxQ7Itxj_AkBNOdsnB6yidc1ZMyO3FzF660xyfix8X-DY-ZjyOBbPLq2KtQ_JDC7tiqxsso5jitPKroIfnS1WaEIqeuOGbcAj8rU3Q8Tj935I7q4u_8yvy-Xt4mZ-sSwtl1yVLVheATQUlVBg66ruraGdQrBV_legBYMgRVXXFqWsQIlKoOlbaKHrZMsPyY_JdxP80xZj0msXLQ6DGdFvo6aSNY1gkouMnk6oDT7GgL3eBLc2Yacp6Lf8dM5P_8svs9_fbbftGrtP8iOwDJxPwLMbcPd_J305v_mwLKcLFxO-fF6Y8Kil4kroh18Lff97Ds3Dz6Ve8Fe0RYkU</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Gouya, Ghazaleh</creator><creator>Siller-Matula, Jolanta M.</creator><creator>Fritzer-Szekeres, Monika</creator><creator>Neuhold, Stephanie</creator><creator>Storka, Angela</creator><creator>Neuhofer, Lisa M.</creator><creator>Clodi, Martin</creator><creator>Hülsmann, Martin</creator><creator>Pacher, Richard</creator><creator>Wolzt, Michael</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201402</creationdate><title>Association of endostatin with mortality in patients with chronic heart failure</title><author>Gouya, Ghazaleh ; Siller-Matula, Jolanta M. ; Fritzer-Szekeres, Monika ; Neuhold, Stephanie ; Storka, Angela ; Neuhofer, Lisa M. ; Clodi, Martin ; Hülsmann, Martin ; Pacher, Richard ; Wolzt, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>All-cause mortality</topic><topic>Biomarkers - metabolism</topic><topic>Chronic Disease</topic><topic>endostatin</topic><topic>Endostatins - metabolism</topic><topic>Epidemiologic Methods</topic><topic>Female</topic><topic>heart failure</topic><topic>Heart Failure - mortality</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Natriuretic Agents - pharmacology</topic><topic>Natriuretic Peptide, Brain - metabolism</topic><topic>Natriuretic Peptide, Brain - pharmacology</topic><topic>Peptide Fragments - metabolism</topic><topic>Prognosis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gouya, Ghazaleh</creatorcontrib><creatorcontrib>Siller-Matula, Jolanta M.</creatorcontrib><creatorcontrib>Fritzer-Szekeres, Monika</creatorcontrib><creatorcontrib>Neuhold, Stephanie</creatorcontrib><creatorcontrib>Storka, Angela</creatorcontrib><creatorcontrib>Neuhofer, Lisa M.</creatorcontrib><creatorcontrib>Clodi, Martin</creatorcontrib><creatorcontrib>Hülsmann, Martin</creatorcontrib><creatorcontrib>Pacher, Richard</creatorcontrib><creatorcontrib>Wolzt, Michael</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gouya, Ghazaleh</au><au>Siller-Matula, Jolanta M.</au><au>Fritzer-Szekeres, Monika</au><au>Neuhold, Stephanie</au><au>Storka, Angela</au><au>Neuhofer, Lisa M.</au><au>Clodi, Martin</au><au>Hülsmann, Martin</au><au>Pacher, Richard</au><au>Wolzt, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of endostatin with mortality in patients with chronic heart failure</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2014-02</date><risdate>2014</risdate><volume>44</volume><issue>2</issue><spage>125</spage><epage>135</epage><pages>125-135</pages><issn>0014-2972</issn><eissn>1365-2362</eissn><abstract>Background
Experimental data imply that in decompensated heart failure (HF), the anti‐angiogenic factor endostatin is increased. This study aimed to investigate whether the angiogenesis inhibitor endostatin is related to the risk of all‐cause mortality in a prospective cohort study of chronic HF patients.
Methods
In this prospective observational cohort study, endostatin serum concentrations were determined in patients with chronic HF. Mortality data were recorded during a median follow‐up of 31 months.
Results
One fifty one patients were included. The overall mortality rate was 20%. Baseline endostatin concentrations > 245 ng/mL were associated with higher risk of all‐cause mortality [HR 8·7 (95% CI 2·5–30·0); P = 0·001] in the multivariate analysis as compared to endostatin concentrations ≤ 245 ng/mL. When both endostatin and NT‐proBNP were above the calculated cut‐off of 245 ng/mL and 2386 pg/mL, respectively, the prognostic utility of both biomarkers increased [HR 40·8 (95% CI 4·7–354·6); P = 0·001] compared with values lower than the cut‐offs.
Conclusions
Serum endostatin concentrations are independently associated with all‐cause mortality. Furthermore, combination of endostatin and NT‐proBNP discriminates patients at high risk.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24188329</pmid><doi>10.1111/eci.12197</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2972 |
| ispartof | European journal of clinical investigation, 2014-02, Vol.44 (2), p.125-135 |
| issn | 0014-2972 1365-2362 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1629952635 |
| source | Wiley |
| subjects | Adult All-cause mortality Biomarkers - metabolism Chronic Disease endostatin Endostatins - metabolism Epidemiologic Methods Female heart failure Heart Failure - mortality Hospitalization - statistics & numerical data Humans Male Middle Aged Natriuretic Agents - pharmacology Natriuretic Peptide, Brain - metabolism Natriuretic Peptide, Brain - pharmacology Peptide Fragments - metabolism Prognosis Young Adult |
| title | Association of endostatin with mortality in patients with chronic heart failure |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A53%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20endostatin%20with%20mortality%20in%20patients%20with%20chronic%20heart%20failure&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Gouya,%20Ghazaleh&rft.date=2014-02&rft.volume=44&rft.issue=2&rft.spage=125&rft.epage=135&rft.pages=125-135&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1111/eci.12197&rft_dat=%3Cproquest_cross%3E1629952635%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3637-b0c340091e7570c848fca1d7e0c49725ec0ae065488ce66407545eafb0b0dd6b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1629952635&rft_id=info:pmid/24188329&rfr_iscdi=true |